No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
EGRX Eagle Pharmaceuticals
- 3.850
- +0.030+0.79%
Close Jun 14 16:00 ET
- 3.830
- -0.020-0.52%
Post 17:58 ET
49.89MMarket Cap4.38P/E (TTM)
3.940High3.760Low127.22KVolume3.830Open3.820Pre Close486.89KTurnover1.42%Turnover Ratio1.41P/E (Static)12.96MShares23.52052wk High0.20P/B34.56MFloat Cap3.21052wk Low--Dividend TTM8.98MShs Float104.170Historical High--Div YieldTTM4.71%Amplitude3.210Historical Low3.827Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Eagle Pharmaceuticals Inc Says on May 28, Co Requested Hearing Before Hearings Panel of Nasdaq, Following Delisting Notice From Nasdaq - SEC Filing
Express News | Eagle Pharmaceuticals Shares Are Trading Lower After the Company Announced a Nasdaq Listing Receipt
12 Health Care Stocks Moving In Wednesday's Intraday Session
GainersIGM Biosciences (NASDAQ:IGMS) shares increased by 36.6% to $11.49 during Wednesday's regular session. The market value of their outstanding shares is at $678.1 million. Akso Health Group (NASDA
Express News | Eagle Pharmaceuticals Announces Receipt of Delisting Notification From Nasdaq
Eagle Pharmaceuticals Announces A Trial In Progress Presentation Of Phase 2/3 Study Of Intravenous Amisulpride As Prevention Of Postoperative Nausea And Vomiting In Pediatric Patients At The Upcoming Society For Ambulatory Anesthesia 2024 Annual Meeting
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") today announced that it will deliver a Trial in Progress presentation discussing the ongoing Phase 2/3 study of intravenous amisulp
Sector Update: Health Care Stocks Softer Late Afternoon
Health care stocks eased late Monday afternoon, with the NYSE Health Care Index decreasing 0.1% and the Health Care Select Sector SPDR Fund (XLV) down 0.2%. The iShares Biotechnology ETF (IBB) fell 1.
Comments
$Eagle Pharmaceuticals(EGRX.US$
NEWS
Eagle Pharmaceuticals Announces a Trial in Progress Presentation of Phase 2/3 Study of Intravenous Amisulpride as Prevention of Postoperative Nausea and Vomiting in Pediatric Patients at the Upcoming Society for Ambulatory Anesthesia (SAMBA) 2024 Annual Meeting
NEWS
Eagle Pharmaceuticals Announces a Trial in Progress Presentation of Phase 2/3 Study of Intravenous Amisulpride as Prevention of Postoperative Nausea and Vomiting in Pediatric Patients at the Upcoming Society for Ambulatory Anesthesia (SAMBA) 2024 Annual Meeting
$Eagle Pharmaceuticals(EGRX.US$
NEWS
Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, Florida
WOODCLIFF LAKE, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that data from the Company’s Phase III trial demonstrating the su...
NEWS
Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, Florida
WOODCLIFF LAKE, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that data from the Company’s Phase III trial demonstrating the su...
Despite moving from losses to profitability, Eagle Pharmaceuticals' share price defies logic by keeping a downward trend. Investors should cautiously observe unresolved business challenges, especially considering the company's underperformance worse than its five-year annualized loss of 13%.
Gapping up
In reaction to earnings/guidance:
• $PepsiCo(PEP.US$+2.8%, $E2open Parent(ETWO.US$ +0.7%
Other news:
• $Cango(CANG.US$ +23.5% (approves special dividend of $0.50 per ordinary share or $1 per ADS)
• $El Pollo Loco(LOCO.US$ +12.7% (declares $1.50/sh special div; also authorizes new $20 mln share repurchase program)
• $KnowBe4(KNBE.US$ +11.4% (KnowBe4 is close to a deal to be acquired by Vista Equity Partners according to ...
In reaction to earnings/guidance:
• $PepsiCo(PEP.US$+2.8%, $E2open Parent(ETWO.US$ +0.7%
Other news:
• $Cango(CANG.US$ +23.5% (approves special dividend of $0.50 per ordinary share or $1 per ADS)
• $El Pollo Loco(LOCO.US$ +12.7% (declares $1.50/sh special div; also authorizes new $20 mln share repurchase program)
• $KnowBe4(KNBE.US$ +11.4% (KnowBe4 is close to a deal to be acquired by Vista Equity Partners according to ...
8
$SeaChange International(SEAC.US$
- SeaChange Soars On Triller Merger Speculation, Trump Ties. stock breaking out.
$BLU
- BELLUS Health Stock Surges After Positive Data From Refractory Chronic Cough Trial. Stock almost hit double digits. Looking for break of $9
$Sigmatron International(SGMA.US$
- ON Friday Company reported Q2 EPS $0.69 Up From $0.15 YoY, Sales $100.20M Up From $69.62M YoY. needs to hold $13 support level
$Eagle Pharmaceuticals(EGRX.US$
- Eagle is seeking approval for a generic version of Vasostrict, which is marketed by (ENDP) Par unit and had total U.S. sales of $786 million in 2020.
$Lucid Group(LCID.US$
- stock bouncing off $35 support as expected. Looking for break of $40 to keep moving higher.
- SeaChange Soars On Triller Merger Speculation, Trump Ties. stock breaking out.
$BLU
- BELLUS Health Stock Surges After Positive Data From Refractory Chronic Cough Trial. Stock almost hit double digits. Looking for break of $9
$Sigmatron International(SGMA.US$
- ON Friday Company reported Q2 EPS $0.69 Up From $0.15 YoY, Sales $100.20M Up From $69.62M YoY. needs to hold $13 support level
$Eagle Pharmaceuticals(EGRX.US$
- Eagle is seeking approval for a generic version of Vasostrict, which is marketed by (ENDP) Par unit and had total U.S. sales of $786 million in 2020.
$Lucid Group(LCID.US$
- stock bouncing off $35 support as expected. Looking for break of $40 to keep moving higher.
5
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg